Published in final edited form as:

Pharmacoepidemiol Drug Saf. 2014 September ; 23(9): 918–922. doi:10.1002/pds.3677.

Validity of Psoriatic Arthritis and Capture of Disease Modifying Antirheumatic Drugs in The Health Improvement Network

Alexis Ogdie, MD, MSCE¹, Sara Alehashemi, MD¹, Thorvardur Jon Love, MD, PhD², Yihui Jiang, BA¹, Kevin Haynes, PharmD, MSCE¹, Sean Hennessy, PharmD PhD¹, Hyon Choi, MD, DrPH³, and Joel M. Gelfand, MD, MSCE¹

¹Perelman School of Medicine at the University of Pennsylvania ²University of Iceland ³Boston University

Abstract

Purpose—To examine the validity of diagnostic codes for psoriatic arthritis in The Health Improvement Network (THIN) and to examine the agreement between General Practitioner (GP) report and prescription records for Disease Modifying Antirheumatic Drugs (DMARDs).

Methods—Questionnaires were sent to the GPs of 100 randomly selected patients with at least one medical record code for psoriatic arthritis. The positive predictive value (PPV) for a GP confirmed diagnosis was calculated and alternative algorithms were examined to determine which method resulted in the highest PPV.

Results—The PPV for a single code for psoriatic arthritis was 85% (95%CI: 75.8–91.7%). Adding a prescription for a DMARD increased the PPV to 91% but with a substantial loss in sensitivity. Agreement between GPs and prescription data for use of an oral DMARD was 69%.

Conclusions—The diagnosis codes for psoriatic arthritis used in THIN are valid. All prescriptions for DMARDs may not be accounted for in THIN.

Keywords

Psoriatic Arthritis; Validation; Database; Disease Modifying Antirheumatic Drug (DMARD); Pharmacoepidemiology; The Health Improvement Network

Corresponding Author: Alexis Ogdie, MD, MSCE, Assistant Professor of Medicine and Epidemiology, Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, 8 Penn Tower, 1 Convention Ave, Philadelphia, PA 19104, Phone: 215-615-4375, Fax: 215-662-4500, alexis.ogdie@uphs.upenn.edu.

Conflict of Interest Statement

The remaining authors do not have competing interests.

Prior Postings and Presentations: This paper was presented in poster form at the International Conference on Pharmacoepidemiology in Montreal, CA, on August 26, 2013. In addition, the positive predictive value and a short summary of the methods was published in a manuscript in *Rheumatology* (Oxford) in 2013 (referenced below). However, the survey results have not been published. Only the following sentence from the validation study was published in the *Rheumatology* paper: “Among the 100 GPs of patients with a Read code for PsA selected for query, 87 surveys were returned within 90 days. Seventy-four patients (85.1%, 95% CI 75.8%, 91.7%) had a confirmed diagnosis of PsA. Among these 74 patients, 62 (83.7%) had been seen by a rheumatologist who corroborated the diagnosis.”

INTRODUCTION

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that can cause joint damage and disability (1). Overall, relatively little is known about long term outcomes in PsA from a population-based perspective. With a prevalence of 0.1–0.25% in the general population, large population-based databases offer an opportunity to better understand long term outcomes in this relatively rare disease (2–4).

The Health Improvement Network (THIN), an electronic primary care medical record database in the UK, is a resource for the study of many medical conditions, a variety of which have already been validated (5–7). THIN includes longitudinal data for over 9,000 patients with at least one diagnostic code for psoriatic arthritis between the ages of 18–89, representing the largest population of patients with PsA available for study to date.(9) Psoriasis, in particular, has been extensively studied in THIN and the positive predictive value of a single code is known to be 90%.(8) The prevalence of PsA in THIN and the prevalence of PsA among patients with psoriasis in THIN are similar to a handful of other population based estimates.(9) However, validation studies have not yet been performed.

In studying inflammatory arthritides such as PsA, ascertaining use of disease modifying antirheumatic drugs (DMARDs) is important because these medications may influence long term outcomes. We previously reported that only 50% of patients with diagnostic codes for psoriatic arthritis in THIN had prescription codes for DMARDs.(9) While this is similar to previous reports from other population-based datasets, it is important to understand the degree to which the use of such therapies is recorded in THIN.

The objectives of this study were to a) examine the accuracy of diagnostic codes in the medical record for the true diagnosis of PsA and b) to examine the agreement between prescription codes in the medical record and GP notation of DMARD use in patients with PsA.

METHODS

Study Design

We performed a cross-sectional study within the Health Improvement Network to determine the validity of the diagnosis codes for PsA.

Data Source

The Health Improvement Network is a large medical record database in the United Kingdom (UK).(10) THIN processes data collected by participating GP practices and makes it available for research after removing patient identifiers and performing quality assessments. More than 9 million people in 498 practices with an average of 7 years of follow up per subject are included in the database. Patients in THIN are representative of the general population in the United Kingdom in terms of age, sex, and medical conditions. Information from specialty care may not be captured unless the data are entered by the GP. However, the gatekeeper system in the UK requires that patients see their GP before seeking specialty care and makes the GP the primary contact for all aspects of the patient's care. GPs record data

related to patient care including demographics, medical history, laboratories and other diagnostic tests, and prescriptions.(6)

Study Population

Patients had at least one READ code(11) for PsA (M160.00, M160.11, M160000, M160100, M160200, M160z00), were age 18–89 at the time of sampling, and were cared for in participating practices.

Outcomes

The General Practitioner's (GP) confirmation of the diagnosis was used as the reference standard. Secondary outcomes included confirmation of the diagnosis by a rheumatologist and fulfillment of the CASPAR criteria.

Sampling

Surveys were sent to the GPs of 100 randomly selected patients with a medical code for PsA cared for in practices that agreed to participate in surveys (250 practices, approximately half of practices contributing to THIN). Surveys were mailed in January 2012 by Cegedim's Additional Information Services so that individual patient information was anonymous to the investigators.

Variables

Variables collected from the medical record included age at sampling, sex, date of diagnosis, rheumatology and dermatology consultation codes, history of osteoarthritis (OA) or rheumatoid arthritis (RA), diagnosis codes for psoriasis, and prescriptions for oral disease modifying antirheumatic drugs (DMARDs) (methotrexate, hydroxychloroquine, sulfasalazine, leflunomide, azathioprine, cyclosporine), biologic DMARDs (etanercept, infliximab, adalimumab), and oral corticosteroids. Data from the medical record were collected between 1994 and 2010.

Instrument

GPs were asked to complete a survey (Supplemental Document) to ascertain accuracy of PsA diagnosis, disease characteristics, and history of DMARD use. The survey was designed by dermatologists, rheumatologists, and epidemiologists with assistance from a GP consultant in the UK.

Analysis

Descriptive statistics were used to compare characteristics among responders and non-responders and among those with confirmed PsA and without PsA. The positive predictive value (PPV) and 95% confidence interval were calculated for each algorithm with the GP confirmed diagnosis as the reference standard. Strategies for defining PsA included a) 1 code for PsA, b) 2 codes for PsA, c) 1 code for PsA and 1 code for psoriasis, d) 1 code for PsA and 1 DMARD prescription, e) a code for PsA in the absence of RA or OA, and f) a code for PsA and a code for a rheumatology consultation. Additionally, among patients with a GP response, we calculated the sensitivity and specificity for algorithms b through f. In

this analysis, the presence or absence of the additional requirement (e.g., a second code for PsA) was considered the "test" and the GP's confirmation of the diagnosis was considered the "reference standard." Finally, we examined percent agreement between GP and medical record notation of DMARDs use. Percent agreement was calculated as the number of times the medical record and the GP agreed on the use of DMARDs over the total number of observations.

Ethics Approval

This study was approved by the University of Pennsylvania Institutional Review Board and the Cegedim Scientific Review Committee. Methods conform to the STROBE statement.
(12)

RESULTS

Of the 100 surveys sent, 87 were returned within 90 days. Practitioners who did not respond belonged to different practices than those who did respond, and patients for whom the survey was not returned had a median year of diagnosis 10 years earlier than those patients whose forms were returned – 1987 vs 1997, respectively. Otherwise, there were not significant differences between the characteristics of patients for whom the survey was returned and those for whom the survey was not completed.

The GP confirmed the diagnosis in 74 of 87 patients with at least one diagnosis code for PsA (PPV 85.1%, 95%CI: 75.8–91.7%). Of those with confirmed PsA, 62 (83.7%) had been seen by a rheumatologist who corroborated the diagnosis and 43 met Classification for Psoriatic Arthritis (CASPAR) criteria.⁽¹³⁾ The remaining 31 records did not have enough information to examine CASPAR criteria.

Characteristics of the patients for whom surveys were returned are found in Table 1. Compared to patients with a non-confirmed diagnosis, those with confirmed PsA were more likely to be male, referred to a rheumatologist, and prescribed a DMARD although only the latter was statistically significant ($p=0.049$). The other characteristics were similar between the two groups.

Clinical features of patients with confirmed PsA are shown in Table 2. The median time since diagnosis was approximately 5 years. GPs reported a history of joint swelling in the majority (72%). Among the 74 patients with confirmed PsA, the GP reported "unknown" for all of the PsA features in 6 patients and one patient was noted to have "none" of the features. Body surface area (BSA) of psoriasis was minimal in 39 patient (53%), moderate in 17 (23%), and severe in 14 (19%). The GP did not know the extent of psoriasis in 4 patients (5%). While all but 4 GPs provided a psoriasis BSA, only 74% of patients with confirmed PsA had a code for psoriasis. Many of the other clinical features were not recorded or were noted as unknown by the GP.

Next, alternative algorithms for defining PsA were examined (Table 3). Of the algorithms tested, none had a substantially higher PPV than a single code for PsA except when a DMARD prescription was required (PPV 91%, 76.3–98.1). However, this lowered the

sensitivity (42%) of the algorithm as less than half of subjects had a prescription for a DMARD.

Finally, agreement between prescription records for DMARDs and GP report of DMARD use was examined. Among the 87 patients with a returned survey, 34 (46%) had at least one prescription for an oral DMARD in THIN and all but 3 patients were confirmed to have used DMARDs by the GP (PPV=91%, 95% CI 0.76–0.98). The GP noted a history of oral DMARD use in an additional 20 patients without a prescription record for an oral DMARD in THIN. In 6 patients, the GP did not know the patient's treatment history and these patients did not have prescriptions for DMARDs in THIN. Percent agreement was 66.7% (95% CI: 56–76%). Of the patients with confirmed PsA, none had a prescription record for a biologic DMARD but 6 GPs reported that the patient was using or had used a biologic DMARD. Of note, four of the six had previous prescriptions for oral DMARDs in THIN.

DISCUSSION

In this validation study, we have demonstrated a single READ code for psoriatic arthritis reliably identifies patients with a diagnosis of PsA in THIN with a positive predictive value of 85% using GP confirmation of the diagnosis as the reference standard. Thus, THIN is a valid database for the study of PsA based on this definition. While adding a prescription for a DMARD increased the PPV to 91%, substantially fewer patients met the criteria. Since performing this validation study, we have published a study on mortality among patients with PsA stratified by DMARD prescription receipt.⁽¹⁴⁾ There was no significant difference in mortality between patients with (HR 1.06, 95% CI: 0.95–1.19) vs. without (HR 0.94, 95% CI: 0.80–1.10) a DMARD prescription suggesting that, while a DMARD prescription may slightly increase the PPV, these two populations may be similar.

Strengths of this study include the 87% response rate within a relatively short period of time, random sampling among all enumerated subjects, and ascertainment of clinical variables. GP report of psoriasis BSA mirrors a previous study examining the validity of codes for psoriasis. The results of this study are generalizable to the use of The Health Improvement Network and likely also to the Clinical Practice Research Datalink (CPRD), formerly known as the General Practice Research Database (GPRD), as the two databases use the same data collection system and approximately half of the practices in THIN also participate in CPRD. (6)

Limitations include the possibility of selection bias in that practices agreeing to participate in surveys may be different from practices who do not participate. Next, general practitioners may not be equipped to answer questions about the patient's arthritis, as suggested by the relative lack of information about clinical disease activity in patients with confirmed PsA. And, given the difficulty diagnosing PsA even among rheumatologists, the diagnosis may be incorrect despite GP confirmation. However, the majority of these patients had been seen by a rheumatologist who corroborated the diagnosis. We were unable to collect information from the rheumatologist to support the rheumatologist's diagnosis of PsA including examination findings. Finally, this validation study examines the validity of codes for PsA in representing the presence of actual disease. There are likely patients with a code

for psoriasis who also have PsA but do not have a medical record code for PsA.(15) Unfortunately, we are unable to capture these patients. This is a challenge associated with studying PsA from a population-based perspective.

In conclusion, THIN is a valid database for the study of the psoriatic arthritis. With more than 9000 cases of psoriatic arthritis, this cohort represents a tremendous resource for future studies examining long term outcomes in PsA and risk factors for development of psoriatic arthritis.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding: This project was funded by the American College of Rheumatology Research Foundation. Data from The Health Improvement Network is supported by the Clinical and Translational Science Award at the University of Pennsylvania (8UL1TR000003 from the National Center for Research Resources). Dr. Ogdie was supported by the American College of Rheumatology Research Foundation and NIH K23AR063764. Dr. Hennessy was supported by R01AG025152. Dr. Gelfand was supported by R01HL111293. Dr. Love was supported by The Icelandic Research Fund, #120433021

Dr Gelfand serves as a consultant to Amgen, Abbott, Centocor, Celgene, Novartis, Eli Lilly and Pfizer and has received honoraria; He has received grants from Amgen, Abbott, Pfizer, Eli Lilly, Novartis and Genentech. Dr. Hennessy has consulted for Amgen, Bristol-Myers Squibb, Astra-Zeneca, Millenium Pharmaceuticals, and CSL Behring, and received research funding from Bristol Myers Squibb and Astra-Zeneca.

Cegedim Strategic Data (CSD) Medical Research UK is an expert in UK anonymous patient data. The data was collected by Cegedim and the general practitioners through an anonymized process using Cegedim's Additional Information Services. CSD is a commercial organization that supplies data and trains and supports researchers in the use of primary care patient data. Data are available for use in medical research in the academic setting as well as in industry for a fee which varies depending on the type of data requested. Aside from undergoing ethical review by the Scientific Review Committee at Cegedim, independent academic groups who voluntarily act as an ethical review body, changes to the protocol were not made by the company. We did not receive financial support or other forms of computational or analytical support from Cegedim/THIN.

REFERENCES

1. Siannis F, Farewell V, Cook R, Schentag C, Gladman D. Clinical and radiographic damage in psoriatic arthritis. *Ann Rheum Dis.* 2006; 65(4):478–481. [PubMed: 16126794]
2. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T. Epidemiology of psoriatic arthritis in the population of the United States. *J Am Acad Dermatol.* 2005; 53(4):573. [PubMed: 16198775]
3. Love T, Gudbjornsson B, Gudjonsson J, Valdimarsson H. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. *J Rheumatol.* 2007; 34(10):2082–2088. [PubMed: 17696270]
4. Setty A, Choi H. Psoriatic Arthritis Epidemiology. *Curr Rheumatol Rep.* 2007; 9:449–454. [PubMed: 18177597]
5. Lewis JD, Schinnar R, Bilker WB, Wang X, Strom BL. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. *Pharmacoepidemiol Drug Saf.* 2007; 16:393–401. [PubMed: 17066486]
6. Ogdie, A.; Langan, S.; Parkinson, J.; Dattani, H.; Kostev, K.; Gelfand, J. Medical Record Databases. In: Strom, B.; Kimmel, S.; Hennessy, S., editors. *Pharmacoepidemiology*. 5th ed.. Oxford, UK: Wiley-Blackwell; 2012. p. 224-243.
7. THIN Bibliography. Available at: <http://csdmruk.cegedim.com/THINBibliography.pdf>.

8. Seminara NM, Abuabara K, Shin DB, Langan SM, Kimmell SE, Margolis D, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. *Br J Dermatol*. 2011; 164(3):602–609. [PubMed: 21073449]
9. Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, et al. Prevalence and treatment patterns of psoriatic arthritis in the United Kingdom. *Rheumatology*. 2013; 52(3):568–575. [PubMed: 23221331]
10. The Health Improvement Network: Our Data. Available at: <http://csdmruk.cegedim.com/our-data/our-data.shtml>.
11. Chishom J. The Read clinical classification. *BMJ*. 1990; 300:1092. [PubMed: 2344534]
12. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Epidemiology*. 2007; 18:800–804. [PubMed: 18049194]
13. Taylor W, Helliwell P. Classification Criteria for Psoriatic Arthritis: Development of New Criteria From a Large International Study. *Arth Rheum*. 2006; 54:2665–2673. [PubMed: 16871531]
14. Ogdie A, Haynes K, Troxel A, Love T, Choi H, Gelfand J. Mortality in Patients with Psoriatic Arthritis Compared to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the General Population. *Ann Rheum Dis*. 2012 Epub Ahead (PMID: 23264338).
15. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis among patients with psoriasis. *Arth Care & Research*. 2009; 61(10):1373–1378. [PubMed: 19790120]

Take Home Messages

- The positive predictive value of a diagnostic code for psoriatic arthritis in a UK medical record database, The Health Improvement Network (THIN), was 85% when using the GP confirmation as the reference standard.
- Large medical record databases such as THIN are excellent resources for the study of long term outcomes in large cohorts of patients with psoriatic arthritis.
- Disease modifying anti-rheumatic drug prescriptions are not fully captured in primary care medical record databases such as THIN.

Table 1

Patient Characteristics

	PsA	No PsA	Not Returned
Number	74	13	13
Male N(%)	41 (55%)	4 (31%)	4 (31%)
Age Mean(SD)	56.7 (14.7)	58.1 (12.9)	61.4 (4.3)
Osteoarthritis	17 (23%)	3 (23%)	3 (23%)
Rheumatoid arthritis	12 (16%)	3 (23%)	1 (8%)
Psoriasis	55 (74%)	10 (77%)	11 (85%)
Rheumatology Consultation	52 (70%)	8 (62%)	8 (62%)
PsA Codes			
M160.00 (Psoriatic Arthropathy)	71	12	11
M160.11 (Psoriatic Arthritis)	6	0	0
M160000 (Psoriatic Spondylitica)	0	0	1
M160100 (Distal interphalangeal psoriatic arthropathy)	0	0	0
M160200 (Arthritis mutilans)	0	0	0
M160z00 (Psoriatic Arthropathy NOS)	1	1	1
Number of PsA Codes			
1	39 (53%)	7 (54%)	7 (54%)
2	18 (24%)	4 (31%)	1 (8%)
3+	17 (23%)	2 (15%)	5 (38%)
Oral DMARD Prescription *	31 (42%)	3 (23%)	7 (54%)
Number of DMARD Prescriptions in Medical Record			
0	43 (58%)	10 (77%)	10 (77%)
1	23 (31%)	1 (8%)	1 (8%)
2+	8 (11%)	2 (15%)	2 (15%)

* Refers to an oral DMARD prescription anytime between registration and date of survey.

Table 2

Disease Features Among Patients with Confirmed Psoriatic Arthritis

	Present	Not Present	Unknown
Morning Stiffness	18 (24%)	17 (23%)	37 (50%)
Inflammatory Back Pain	22 (30%)	26 (35%)	26 (35%)
Joint Swelling	53 (72%)	12 (16%)	9 (12%)
Dactylitis or Sausage Digit	13 (18%)	34 (46%)	27 (36%)
Nail Disease	13 (18%)	21 (28%)	40 (54%)
DIP Joint Involvement	20 (27%)	22 (30%)	32 (43%)
Oligoarthritis	26 (35%)	28 (38%)	20 (27%)
Polyarthritis	36 (49%)	23 (31%)	15 (20%)
Spondylitis	7 (9%)	39 (53%)	28 (38%)
Xray Confirmation	9 (12%)	33 (45%)	32 (43%)
Family history of Psoriasis	12 (16%)	13 (18%)	49 (66%)

* This table includes only patients with a diagnosis of PsA confirmed by the GP.

Table 3

Alternative Algorithms for Defining Psoriatic Arthritis

	Total	Confirmed	PPV (%)	95% CI	Sensitivity*	Specificity*
One PsA Code	87	74	85.1	(75.8–91.8)	N/A	N/A
PsA+DMARD	34	31	91.2	(76.3–98.1)	41.9	76.9
PsA+PsO	65	55	84.6	(73.5–92.4)	74.3	23.1
Two PsA Codes	41	35	85.4	(70.8–94.4)	47.3	53.8
PsA & No OA code	67	57	85.1	(74.3–92.6)	77.0	23.1
PsA & No RA code	72	62	86.1	(75.9–93.1)	83.8	23.1
PsA+ Rheum code	59	51	86.4	(75.0–94.0)	68.9	38.5
PsA+PsO+DMARD	27	26	91.2	(76.3–98.1)	35.1	92.3

Abbreviations: PsA = psoriatic arthritis, PsO = psoriasis, OA = osteoarthritis, RA = rheumatoid arthritis, Rheum code = code referring to rheumatology consultation, DMARD = Disease Modifying Antirheumatic Drug.

* These columns represent the sensitivity and specificity of the additional code (e.g. DMARD prescription) for a verified diagnosis of PsA by GP report among patients with at least one code for psoriatic arthritis. They do not represent overall sensitivity and specificity of the algorithm (including the PsA code) as false negatives are unavailable (i.e., we did not sample patients without PsA codes).